Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Taking the stress out of insulin initiation in type 2 diabetes mellitus

Tessa Laubscher, Loren Regier and Brent Jensen
Canadian Family Physician June 2009, 55 (6) 608-611;
Tessa Laubscher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loren Regier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brent Jensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • CFPlus
  • eLetters
  • Info & Metrics
  • PDF
Loading

For many family physicians, initiating insulin therapy in people with type 2 diabetes mellitus (DM) can be anxiety-provoking and time-consuming. Often it is physicians’ lack of confidence in starting insulin, not patients’ fear of insulin injections, that delays optimizing glycemic control. Accessing resources such as diabetes treatment guidelines,1–3 RxFiles Drug Comparison Charts, and the services of pharmacists or diabetes educators can help take the stress out of this important aspect of diabetes care. The current debate over the uncertain benefits and risks of tight glucose control is beyond the scope of this article, but is discussed in the RxFiles “Diabetes—Glucose Control: Landmark Outcome Trials—Summary,” available on CFPlus.*

Case

Tom is a 72-year-old man who has type 2 DM, hypertension, hyperlipidemia, and stable angina. He has had type 2 DM for about 14 years; until recently, his blood glucose (BG) levels were well controlled with combinations of oral hypoglycemic agents (OHAs), diet, and regular exercise. Over the past year his glycosylated hemoglobin A1c (HbA1c) levels have climbed; last month they were measured at 9.2%. This translates to an estimated average glucose (eAG) level of 12.1 mmol/L.4 Recent self-monitored BG readings include the following: fasting 8.9 to 11.2 mmol/L; before lunch 7.8 to 9.2 mmol/L; 1 hour after lunch 10.9 to 13.4 mmol/L; before supper 9.9 to 10 mmol/L.

Current diabetes medications include 1000 mg of metformin twice daily, 30 mg of pioglitazone daily, and 60 mg of gliclazide daily. He is taking optimal therapy for cardiovascular protection, including blood pressure control and statin therapy, which have proven outcome benefits.

In the clinic, you review Tom’s recent HbA1c and BG values; he informs you that he is following the diet guidelines recommended by the dietitian 6 months ago and is exercising for 30 to 60 minutes most days. A recent 2-kg weight loss confirms Tom’s lifestyle management progress. Tom asks you, “What else can I do to improve my blood sugars?”

While it is tempting to avoid the “inconvenience” of initiating insulin therapy at this clinic visit, it might be the preferred option for pursuing glycemic control. Tom is already taking adequate doses of 3 classes of OHAs.5 Further dose increases are unlikely to result in substantial reduction in glucose levels and might increase his risk of side effects. Sitagliptin could be considered, given its postprandial effect and minimal weight gain; however, it lacks outcome evidence and long-term safety data and reduces HbA1c by only about 0.7%.6 There is no evidence supporting its role as an add-on therapy to 3 other classes of OHAs.

Type 2 diabetes is characterized by insulin resistance and progressive decline in pancreatic β-cell function and endogenous insulin production.1 Physicians and patients need to acknowledge the progressive nature of type 2 DM and make appropriate advances in diabetic therapy (diet and lifestyle → OHAs → insulin). Because he has had type 2 DM for 14 years, Tom’s pancreas might not be able to produce adequate amounts of insulin even with additional OHA therapy. Thus insulin is an appropriate step-up therapy.

Successful initiation of insulin might be facilitated by the following considerations7,8:

  • Explain the rationale for starting insulin, emphasizing the progressive nature of type 2 DM and not blaming the patient. A demonstration of how insulin injections can be easily administered with a pen device allays many fears and misconceptions that people have about insulin, needles, and syringes (Box 19).

  • To avoid large drops in BG levels and ensure patient adherence, start with a low dose of basal insulin (eg, intermediate-acting insulin) at 5 to 10 units or 0.1 to 0.2 units/kg total body weight at bedtime. Give the patient written instructions on titrating the dose (eg, increase by 2 units every 3 days until fasting glucose < 7 mmol/L).1 Avoid dosage increases if the patient experiences nocturnal hypoglycemia or 2 or more episodes of BG levels below 4 mmol/L.

  • Contact the patient’s pharmacist or diabetes educator and ask him or her to provide instruction on use of the insulin delivery device and dosage adjustment if you are not able to do this in your practice.

  • Metformin therapy should generally be continued when initiating insulin if it is not contraindicated (eg, in acute heart failure). Metformin has outcome evidence for reduced mortality, results in less weight gain from insulin, and might decrease the required insulin dose.10,11 Thus metformin can be continued even with multiple daily insulin injection regimens. Caution and dose reduction are required in patients with moderate renal impairment (creatinine clearance 30 to 60 mL/min).1,2

  • Sulfonylureas (eg, gliclazide) might contribute to glycemic control when once-daily basal insulin is used, but should usually be discontinued if mealtime short-acting or rapid insulin is added. Thiazolidinediones (eg, pioglitazone, rosiglitazone) are not approved for use with insulin and are usually discontinued owing to the increased risks of edema, heart failure, and weight gain.12,13

  • Hypoglycemia is rare in patients with type 2 DM taking combinations of metformin and basal intermediate- or long-acting insulin. However, all patients using insulin should learn the risks, symptoms, and treatment of hypoglycemia.1,7

  • Self-monitoring of BG needs to be individualized.1,7 Type 2 DM patients taking insulin will need to monitor BG more frequently. Preprandial and postprandial BG levels are required to decide if and when to start mealtime insulin therapy.

  • Individualize treatment goals balancing uncertain benefits with potential risks and difficulties of tighter glucose control.1,14

Box 1

Starting insulin in type 2 diabetes mellitus: Tips for patient buy-in

  • Discuss insulin early to change negative perceptions about insulin

  • Provide information about insulin benefits

  • Consider suggesting a “trial” for 1 month

  • Discuss the relative ease of using the newer insulin devices (eg, insulin pens, smaller needle) compared with syringes and vials (see also RxFiles Insulin Pen Delivery Devices chart at www.RxFiles.ca*)

  • Link patient to community support, such as a certified diabetes educator, for education on injections and monitoring

  • Ensure patient has time to get comfortable with loading and working a pen (or syringe)

  • Refer patient for nutrition and physical activity counseling

  • Adapted from Starting Insulin.9

  • Most patients with type 2 DM have few problems with insulin therapy when it is started once daily in addition to metformin. Once comfortable with basal insulin therapy, they are more willing to accept the introduction of bolus (short-acting or rapid) insulin (Table 18) before meals for better postprandial glycemic control.1,2

    View this table:
    • View inline
    • View popup
    Table 1

    Insulin available in Canada

    There is some debate about the role of long-acting insulin analogues (LAIAs) in the initiation of basal insulin therapy in patients with type 2 DM. While some authors suggest a prominent role, recent systematic reviews have found that LAIAs offer little advantage over neutral protamine Hagedorn (NPH) for initial therapy.15–18 The primary advantage of LAIAs is the potential for less nocturnal hypoglycemia in some patients; HbA1c and weight end points are similar to those seen with intermediate-acting insulin15,16 and outcome evidence is lacking. Newer LAIAs cost more than twice as much as intermediate-acting insulin (Table 18). Further advantages and disadvantages of the different types of insulin are outlined in Table 2.15–22

    View this table:
    • View inline
    • View popup
    Table 2

    Advantages and disadvantages of insulin: Evidence for insulin analogues is limited to small, short-term trials, and benefits are modest; anecdotal experience is favourable. Recent systematic and economic reviews rigorously assessed benefits, risks, and incremental cost.15–22

    RxFiles is an academic detailing program providing objective comparative drug information. RxFiles incorporates information from family physicians, other specialists, and pharmacists with an extensive review of the literature to produce newsletters, question-and-answer summaries, trial summaries, and drug comparison charts. The RxFiles Drug Comparison Charts book and website have become practical tools for evidence-based and clinically relevant drug use information throughout Canada. For more information, go to www.RxFiles.ca.

    Footnotes

    • ↵* The “Diabetes—Glucose Control: Landmark Outcome Trials—Summary,” the insulin pen delivery devices chart, an approach to management of type 2 diabetes in adults chart, an insulin comparison chart, and “Insulin Management: Evidence, Tips & Pearls” are available at www.cfp.ca. Go to the full text of the article on-line, then click on CFPlus in the menu at the top right of the page.

    • Competing interests

      RxFiles and contributing authors do not have any commercial competing interests. RxFiles Academic Detailing Program is funded through a grant from Saskatchewan Health to Saskatoon Health Region; additional “not for profit; not for loss” revenue is obtained from sale of books and on-line subscriptions.

    • Copyright© the College of Family Physicians of Canada

    References

    1. 1.↵
      1. Canadian Diabetes Association
      Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in CanadaCan J Diabetes200832Suppl 1S1201. Available from: www.diabetes.ca/files/cpg2008/cpg-2008.pdf. Accessed 2009 Apr 21.
      OpenUrl
    2. 2.↵
      1. American Diabetes Association
      Standards of medical care in diabetes—2008. Diabetes Care200932Suppl 1S1254. Available from: http://care.diabetesjournals.org/content/vol31/Supplement_1/. Accessed 2009 Apr 21.
      OpenUrl
    3. 3.↵
      1. Nathan DM,
      2. Buse JB,
      3. Davidson MB,
      4. Ferrannini E,
      5. Holman RR,
      6. Sherwin R,
      7. et al.
      Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2009321193203. Available from: http://care.diabetesjournals.org/cgi/reprint/32/1/193. Accessed 2009 Apr 27.
      OpenUrlAbstract/FREE Full Text
    4. 4.↵
      1. Nathan DM,
      2. Kuenen J,
      3. Borg R,
      4. Zheng H,
      5. Schoenfeld D,
      6. Heine RJ
      Translating the A1c assay into estimated average glucose valuesDiabetes Care200831814738. Available from: http://professional.diabetes.org/Glucosecalculator.aspx. Accessed 2009 Apr 27.
      OpenUrlAbstract/FREE Full Text
    5. 5.↵
      1. Regier L,
      2. Jensen B
      Oral hypoglycemic agents comparison chartRxFiles drug comparison charts7th edSaskatoon, SKSaskatoon Health Region200825Available from: wwwRxFilesca Accessed 2009 Apr 27.
    6. 6.↵
      RichterBBandeira-EchtlerEBergerhoffKLerchCLDipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusCochrane Database Syst Rev20082CD006739
    7. 7.↵
      1. Jin M,
      2. Regier L,
      3. Jensen B
      RxFiles insulin management: evidence, tips & pearlsRxFiles drug comparison charts7th edSaskatoon, SKSaskatoon Health Region200826b7. Available from: www.RxFiles.ca. Accessed 2009 Apr 17.
    8. 8.↵
      1. Regier L,
      2. Jensen B,
      3. Downey S
      Insulin comparison chartRxFiles drug comparison charts7th edSaskatoon, SKSaskatoon Health Region200826b7. Available from: www.RxFiles.ca. Accessed 2009 Apr 17.
    9. 9.↵
      Knowledge Support Service, Centre for Effective PracticeStarting insulinToronto, ONDepartment of Family and Community Medicine, University of Toronto2008
    10. 10.↵
      UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet1998352913185465
      OpenUrlCrossRefPubMed
    11. 11.↵
      Yki-JärvinenHRyysyLNikkiläKTulokasTVanamoRHeikkiläMComparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trialAnn Intern Med1999130538996
      OpenUrlCrossRefPubMed
    12. 12.↵
      e-CPS [database on the Internet]Ottawa, ONCanadian Pharmacists Association2009
    13. 13.↵
      NestoRWBellDBonowROFonsecaVGrundySMHortonESThiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes AssociationDiabetes Care200427125663
      OpenUrlFREE Full Text
    14. 14.↵
      1. Montori V,
      2. Fernandez-Balsells M
      Glycemic control in type 2 diabetes: time for an evidence-based about face?Ann Int Med200915011Epub ahead of print. Available from: www.annals.org/cgi/content/full/0000605200906020-00118v1. Accessed 2009 Apr 21.
    15. 15.↵
      HorvathKJeitlerKBergholdAEbrahimSHGratzerTWPlankJLong-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusCochrane Database Syst Rev20072CD005613
    16. 16.↵
      Canadian Agency for Drugs and Technologies in Health. Optimal therapy recommendations for the prescribing and use of insulin analoguesCan Optimal Med Prescr Util Serv200927179. Available from: www.cadth.ca/media/pdf/compus_IA_OT_rec_report.pdf. Accessed 2009 Apr 14.
      OpenUrl
    17. 17.
      SchooffMDGuptaLAre long-acting insulin analogues better than isophane insulin?Am Fam Physician20087744479
      OpenUrlPubMed
    18. 18.↵
      Canadian Agency for Drugs and Technologies in Health. An economic evaluation of insulin analogues for the treatment of patients with type 1 and type 2 diabetes mellitus in CanadaCan Optimal Med Prescr Util Serv200824152. Available from: www.cadth.ca/media/compus/reports/compus_Economic_IA_Report.pdf. Accessed 2009 Apr 17.
      OpenUrl
    19. 19.
      SiebenhoferAPlankJBergholdAJeitlerKHorvathKNarathMShort acting insulin analogues versus regular human insulin in patients with diabetes mellitusCochrane Database Syst Rev20062CD003287
    20. 20.↵
      QayyumRBolenSMaruthurNFeldmanLWilsonLMMarinopoulosSSSystematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetesAnn Intern Med2008149854959
      OpenUrlCrossRefPubMed
    21. 21.↵
      RollaAPharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safetyAm J Med20081216 SupplS919
      OpenUrlCrossRefPubMed
    22. 22.↵
      SinghSAhmadFLalAYuCBaiZBennettHEfficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysisCMAJ2009180438597
      OpenUrlAbstract/FREE Full Text
    PreviousNext
    Back to top

    In this issue

    Canadian Family Physician: 55 (6)
    Canadian Family Physician
    Vol. 55, Issue 6
    1 Jun 2009
    • Table of Contents
    • About the Cover
    • Index by author
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Taking the stress out of insulin initiation in type 2 diabetes mellitus
    (Your Name) has sent you a message from The College of Family Physicians of Canada
    (Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Taking the stress out of insulin initiation in type 2 diabetes mellitus
    Tessa Laubscher, Loren Regier, Brent Jensen
    Canadian Family Physician Jun 2009, 55 (6) 608-611;

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Respond to this article
    Share
    Taking the stress out of insulin initiation in type 2 diabetes mellitus
    Tessa Laubscher, Loren Regier, Brent Jensen
    Canadian Family Physician Jun 2009, 55 (6) 608-611;
    Reddit logo Twitter logo Facebook logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Case
      • Footnotes
      • References
    • Figures & Data
    • CFPlus
    • Info & Metrics
    • eLetters
    • PDF

    Related Articles

    • PubMed
    • Google Scholar

    Cited By...

    • No citing articles found.
    • Google Scholar

    More in this TOC Section

    Practice

    • Determining if and how older patients can safely stay at home with additional services
    • Managing type 2 diabetes in primary care during COVID-19
    • Effectiveness of dermoscopy in skin cancer diagnosis
    Show more Practice

    RxFiles

    • Une administration inappropriée
    • Improper administration
    • L’asthme léger chez les adultes et les adolescents
    Show more RxFiles

    Similar Articles

    Navigate

    • Home
    • Current Issue
    • Archive
    • Collections - English
    • Collections - Française

    For Authors

    • Authors and Reviewers
    • Submit a Manuscript
    • Permissions
    • Terms of Use

    General Information

    • About CFP
    • About the CFPC
    • Advertisers
    • Careers & Locums
    • Editorial Advisory Board
    • Subscribers

    Journal Services

    • Email Alerts
    • Twitter
    • RSS Feeds

    Copyright © 2023 by The College of Family Physicians of Canada

    Powered by HighWire